|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:awards
|
gptkb:German_Future_Prize_(2021)
|
|
gptkbp:CEO
|
gptkb:Uğur_Şahin
|
|
gptkbp:collaboratedWith
|
gptkb:Pfizer
gptkb:Bill_&_Melinda_Gates_Foundation
gptkb:Sanofi
gptkb:Fosun_Pharma
gptkb:Regeneron
gptkb:Genentech
gptkb:Roche
|
|
gptkbp:country
|
gptkb:Germany
|
|
gptkbp:COVID-19_vaccine_approval
|
December 2020 (EU, US, UK)
|
|
gptkbp:focus
|
infectious diseases
immunotherapy
mRNA therapeutics
|
|
gptkbp:founded
|
2008
|
|
gptkbp:founder
|
gptkb:Uğur_Şahin
gptkb:Özlem_Türeci
gptkb:Christoph_Huber
|
|
gptkbp:headquarters_location
|
gptkb:Mainz,_Germany
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
BioNTech Group
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:IPODate
|
October 2019
|
|
gptkbp:legalForm
|
Societas Europaea
|
|
gptkbp:listed_in_index
|
gptkb:NASDAQ_Biotechnology_Index
|
|
gptkbp:listedOn
|
gptkb:NASDAQ
|
|
gptkbp:marketCap
|
over $20 billion (2023)
|
|
gptkbp:notableEvent
|
IPO in 2019
Developed first approved mRNA COVID-19 vaccine
Expansion into Asia and US markets
Major partnership with Pfizer
Rapid scale-up during COVID-19 pandemic
Received German Future Prize in 2021
|
|
gptkbp:notablePerson
|
gptkb:Uğur_Şahin
gptkb:Özlem_Türeci
gptkb:Christoph_Huber
|
|
gptkbp:notableProduct
|
gptkb:BNT162b2
vaccine
|
|
gptkbp:numberOfEmployees
|
over 3,000 (2023)
|
|
gptkbp:parentOrganization
|
gptkb:BioNTech_SE
|
|
gptkbp:publiclyTraded
|
yes
|
|
gptkbp:researchArea
|
gene therapy
antibodies
personalized cancer vaccines
small molecule immunomodulators
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ
|
|
gptkbp:stockSymbol
|
gptkb:BNTX
|
|
gptkbp:subsidiary
|
gptkb:BioNTech_US_Inc.
|
|
gptkbp:website
|
https://biontech.com
|
|
gptkbp:bfsParent
|
gptkb:BioNTech_SE
|
|
gptkbp:bfsLayer
|
6
|